Precision Protection for Poultry, Enabling Smarter Disease Control

 DIFF-DIVA H9 is a first-in-class inactivated avian influenza vaccine designed to differentiate vaccinated birds from naturally infected ones, solving a critical challenge in global poultry health.

 
Core Technology

Using a proprietary reverse genetics system, we have inserted the Influenza B neuraminidase (NA) gene as a stable genetic tag into the backbone of an avian influenza A virus (H9 strain).

 
The DIVA Principle

Only birds immunized with DIFF-DIVA H9 produce antibodies against the Influenza B NA marker. Natural infection with field strains does not induce these antibodies, enabling accurate monitoring and supporting progressive disease control strategies.

Figure 1. Immunofluorescence Assay for Serological Differentiation of Infected from

Vaccinated Animals (DIVA)

Why DIFF-DIVA H9 Stands Out

• Versatile Platform: Applicable to H5, H7, and H9 strains, supporting broad disease control.
• Safe & Robust:Stable genetic markers ensure high safety and strong immune protection.
• Supports Eradication: Enables accurate monitoring, outbreak containment, and progress toward disease-free certification.
• Market-Ready: Designed for global poultry markets requiring DIVA-compliant vaccines.

 

DIFF-DIVA H9 is more than a vaccine — it is part of an integrated solution. We provide a comprehensive strategy of "DIVA vaccines + discriminatory diagnostics + regional eradication." This approach aims to reshape the avian influenza control landscape by realigning the entire industry chain towards sustainable disease elimination.